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WHAT IS TORS?
• Transoral Robotic Surgery (TORS) is a minimally invasive approach to
the treatment of oral, throat, and skull base cancers
• Contrast to traditional open surgical approaches, primary defects in
TORS are left open to heal by secondary intention
• Subsequent to its emergence, a variety of reports demonstrated that
the risk of postoperative hemorrhage range from 3.6-18.5%
• Neck vessel ligation has been an increasingly adopted technique as a
means to prophylactically decrease the risk of severe life-threatening
bleeds

STUDY DESIGN
• We performed a survey in which 165 members of AHNS completed 10
questions focusing on their experiences with TORS
• Questions included length of time performing TORS, number of TORS
completed since residency/fellowship and per year, reasons for vessel
ligation, changes in ligation practices, as well as incidence of
hemorrhage

•
•
•
•

How many TORS cases for cancerrelated diagnosis per year?

Percent

Percent

How long have you performed TORS?

55.8% reported 3-6 years
26.7% reported 1-3 years
8.5% reported <1 year
9.1% reported prior to 2009 FDA approval

• 38% reported performing 10-20
procedures per year
• 14% reported performing 21-30 per year
• 37% reported performing <10 per year

Which vessels are ligated?

• 77.6% reported ligating the lingual artery
• 63% reported ligating the facial artery

Reasons for vessel ligation

• 28.5% due to discussion with peers without personally
experiencing bad outcome

• 29.7% reported ligating the ascending pharyngeal artery

• 14.5% due to fatality/near fatality in their own or partner’s
patient

• 12.7% reported ligating the superior thyroid artery

• 28.5% adopted it from training

• 8.5% reported ligating the external carotid artery

RESULTS CONT’D.
• Unligated vessels:
• Life-threatening bleeds (Grade IV) in 21.2% of cases
• Death secondary to bleed (Grade V) in 9.1% of cases
• Bleeding that was easily managed in the OR (Grade III) in 42% of cases

• Ligated vessels:
• Life-threatening bleeds (Grade IV) in 6.1% of cases
• Death secondary to bleed (Grade V) in 1.8% of cases
• Bleeding that was easily managed in the OR (Grade III) in 33.3% of cases

DISCUSSION
• Although there was a strong agreement amongst the surgeons with
regards to prophylactic vessel ligation, there was an appreciable
variation when choosing which vessel to ligate, the most common
being the lingual artery
• Of note, 15% of respondents did not incorporate vessel ligation into
their practice, citing futility in light of the bilateral blood supply

WHAT’S IN THE LITERATURE?

LIMITATIONS AND FUTURE WORK
• As with any survey, there is potential for bias
• The survey focused on members of AHNS, who may not be
representative of other surgeons
• Future work should focus multi-center protocols for vessel ligation
incorporating larger numbers of cases to obtain more powerful data
• The choice of which vessels to ligate and their relative associations
with risk of hemorrhage should be further explored as it remains
controversial and subjective

QUESTIONS?

Thank you!
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